Seedlabs

Post-Ablation Chaperokine Response Blood Test

A blood test that tracks how the immune system responds after a tumor is burned away.

A serial blood test that measures extracellular Hsp72 and the Hsp70-dependent immune-activating capacity of patient serum after tumor ablation, giving interventional-oncology trials a mechanistic readout of the 'in situ vaccination' effect.

Biochemistry, Genetics and Molecular BiologyHeat shock proteins research
Metabolism and Genetic DisordersInterventional oncology clinical trials — mechanism-of-action biomarker for tumor ablation and ablation + checkpoint-inhibitor combinations.

Concept

A clinical-trial blood test for patients undergoing tumor ablation (irreversible electroporation, cryoablation, radiofrequency ablation). Ablation kills tumor cells largely through necrotic death; per the source review, necrosis passively releases Hsp70, which then engages TLR2/4-CD14, CD36, CD91, LOX-1, SR-A and CD40 on antigen-presenting cells to initiate an immune response — the mechanistic basis of so-called in situ vaccination. The test draws blood pre-ablation and at fixed post-procedure timepoints, then (a) quantifies serum extracellular Hsp72 and (b) applies the serum to a standardized antigen-presenting-cell reporter line with and without Hsp70 immunodepletion or receptor blockade, isolating the Hsp70-dependent fraction of immune activation. The output — a Chaperokine Response Score per timepoint — gives ablation-device makers and pharma combination-trial teams an objective, mechanism-linked endpoint, and a basis for stratifying which patients are candidates for ablation plus checkpoint-inhibitor therapy. Deployed first as a research-use / trial-endpoint assay.

Why now

Paper [0] demonstrates that Hsp70 is released by passive necrotic mechanisms and that binding to its defined receptor set is the prerequisite for initiating the host immune response — i.e., it specifies exactly what to measure in blood after a necrosis-inducing procedure: circulating eHsp72 level and receptor-mediated activation of antigen-presenting cells. Older paper [2] confirms the functional readout: TLR signaling in antigen-presenting cells produces inflammatory cytokines, which is the reporter line's primary signal.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 2 papers87

A highly focused, mechanistically grounded diagnostic tool for interventional oncology trials that transforms a vague 'in situ vaccination' concept into a quantifiable biomarker.

Evidence strength
5/5
The idea directly maps the necrotic release of Hsp70 and its specific receptor-mediated activation of APCs described in the research to a concrete measurement protocol.
Market pull
4/5
Device makers and pharma companies have a strong incentive to prove the mechanism of action for ablation-based therapies to justify higher pricing and combination trial success.
Novelty & moat
4/5
While it shares a mechanism with the 'Lot-Release Assay' in the catalog, it applies it to a completely different user (clinical trials) and a different value proposition (patient response vs. reagent potency).
Feasibility
3/5
Quantifying Hsp72 is straightforward, but maintaining a standardized APC reporter line for serum testing adds significant operational complexity to the MVP.
Wedge clarity
5/5
The wedge is extremely sharp: a research-use endpoint for specific interventional oncology clinical trials.
Simplicity / focus
5/5
The product is a single, focused assay with one clear purpose, avoiding any 'platform' creep.

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • AngioDynamicscompany

    Its NanoKnife irreversible-electroporation platform induces necrotic tumor cell death; a blood-based immune-response readout would give its immunotherapy-combination trials an objective mechanistic endpoint.

  • IceCure Medicalcompany

    Runs cryoablation trials in breast and lung tumors; a Chaperokine Response Score provides a systemic immune-engagement endpoint beyond local tumor control.

  • Profound Medicalcompany

    Its TULSA-PRO ablation system would benefit from a quantified, mechanism-linked measure of the immune response triggered by ablated tissue death.

  • Merck & Co.company

    Operates many pembrolizumab combination trials; a biomarker identifying patients who mount an endogenous Hsp70-driven immune response after ablation could enrich ablation + PD-1 study populations.

Research it builds on

  1. Exercise and Toll-like receptors
    Michael Gleeson, Brian Keith McFarlin, Michael G. Flynn · 2026 · 254 citations
    All ideas from this paper →
  2. Stress proteins and initiation of immune response: Chaperokine activity of Hsp72
    Alexzander A. A. Asea · 2026 · 157 citations
    All ideas from this paper →
Leave feedback
feasibility